328 related articles for article (PubMed ID: 1692727)
21. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis of HIV-1 infection by detection of antibody IgG to HIV-1 in urine with ultrasensitive enzyme immunoassay (immune complex transfer enzyme immunoassay) using recombinant proteins as antigens.
Hashida S; Hashinaka K; Saitoh A; Takamizawa A; Shinagawa H; Oka S; Shimada K; Hirota K; Kohno T; Ishikawa S
J Clin Lab Anal; 1994; 8(4):237-46. PubMed ID: 7523637
[TBL] [Abstract][Full Text] [Related]
23. [Dynamics of the antibody response and p24 antigenemia in HIV-1 infected individuals in Czechoslovakia].
Kopecká D; Brůcková M; Stanková M; Syrůcek L; Vojtĕchovský K; Petkov V
Cesk Epidemiol Mikrobiol Imunol; 1990 Mar; 39(2):65-73. PubMed ID: 2142624
[TBL] [Abstract][Full Text] [Related]
24. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
Ota A; Tanaka-Taya K; Ueda S
Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
[TBL] [Abstract][Full Text] [Related]
25. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1.
Thomas HI; Wilson S; O'Toole CM; Lister CM; Saeed AM; Watkins RP; Morgan-Capner P
Clin Exp Immunol; 1996 Feb; 103(2):185-91. PubMed ID: 8565298
[TBL] [Abstract][Full Text] [Related]
26. Identification of a potent synthetic HIV1 immunogen compromising gag-P24 tandem T- and B-cell epitopes.
Chong P; Sia C; Sydor M; Klein M
FEBS Lett; 1990 May; 264(2):231-4. PubMed ID: 1694143
[TBL] [Abstract][Full Text] [Related]
27. A peptide library expressed in yeast reveals new major epitopes from human immunodeficiency virus type 1.
Madaule P; Gairin JE; Bénichou S; Rossier J
FEMS Microbiol Immunol; 1991 Apr; 3(2):99-107. PubMed ID: 1713777
[TBL] [Abstract][Full Text] [Related]
28. A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: immunoglobulin G titre and avidity are early predictors of clinical course.
Chargelegue D; Colvin BT; O'Toole CM
AIDS; 1993 Nov; 7 Suppl 2():S87-90. PubMed ID: 7909231
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
30. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study.
Sei Y; Tsang PH; Roboz JP; Sarin PS; Wallace JI; Bekesi JG
J Clin Immunol; 1988 Nov; 8(6):464-72. PubMed ID: 3146584
[TBL] [Abstract][Full Text] [Related]
31. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection].
Sorice F; Vullo V; Cirelli A; Catania S; Mastroianni CM; Contini C; Delia S
Boll Ist Sieroter Milan; 1989; 68(2):115-21. PubMed ID: 2562362
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory mechanism of anti-P30-52 monoclonal antibody against human immunodeficiency virus type 1 (HIV-1) multiplication in infected MT-4 cells.
Ota A; Ueda S
Hybridoma; 1999 Jun; 18(3):235-41. PubMed ID: 10475237
[TBL] [Abstract][Full Text] [Related]
33. Human monoclonal antibodies to HIV-1: cross-reactions with gag and env products.
Pollock BJ; McKenzie AS; Kemp BE; McPhee DA; D'Apice AJ
Clin Exp Immunol; 1989 Dec; 78(3):323-8. PubMed ID: 2482145
[TBL] [Abstract][Full Text] [Related]
34. Random expression of human immunodeficiency virus-1 (HIV-1) p17 (epitopes) on the surface of the HIV-1-infected cell.
Ota A; Liu X; Fujio H; Sakato N; Ueda S
Hybridoma; 1998 Feb; 17(1):73-5. PubMed ID: 9523241
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of specific antibodies to human immunodeficiency virus structural proteins: clinical significance.
Allain JP; Laurian Y; Einstein MH; Braun BP; Delaney SR; Stephens JE; Daluga CK; Dahlen SJ; Knigge KM
Blood; 1991 Mar; 77(5):1118-23. PubMed ID: 1671648
[TBL] [Abstract][Full Text] [Related]
36. [Anti-HIV-1 p17 antibody as anti-HIV agent].
Tsuchie H; Tochikura A; Kageyama S; Kurimura T
Nihon Rinsho; 1993 Sep; 51 Suppl():213-8. PubMed ID: 8271386
[No Abstract] [Full Text] [Related]
37. Three antigenic regions in p17 of human immunodeficiency virus type 1 (HIV-1) revealed by mouse monoclonal antibodies and human antibodies in HIV-1 carrier sera.
Liu X; Ota A; Watanabe M; Ueda S; Saitoh A; Shinagawa H; Nakata A; Kurimura T; Wang X; Zhao Y
Microbiol Immunol; 1995; 39(10):775-85. PubMed ID: 8577268
[TBL] [Abstract][Full Text] [Related]
38. Plasma viremia in human immunodeficiency virus infection.
Coombs RW; Collier AC; Allain JP; Nikora B; Leuther M; Gjerset GF; Corey L
N Engl J Med; 1989 Dec; 321(24):1626-31. PubMed ID: 2511447
[TBL] [Abstract][Full Text] [Related]
39. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
40. Correlation of serum antigen and antibody concentration with clinical features in HIV infection.
Ellaurie M; Rubinstein A
Arch Dis Child; 1991 Feb; 66(2):200-3. PubMed ID: 1705767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
